Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A view on drug resistance in cancer
    Review

    Vasan, N.; Baselga, J.; Hyman, D. M.
    Nature (2019)

    Fulltext@MSK | Save
  • Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis
    Journal Article

    Rodrigues, G.; Hoshino, A.; Kenific, C. M.; Matei, I. R.; Steiner, L.; Freitas, D.; Kim, H. S.; Oxley, P. R.; Scandariato, I.; Casanova-Salas, I.; more...
    Nature Cell Biology (2019)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors
    Journal Article

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Science (2019)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR plus ) TNBC
    Meeting Abstract

    Traina, T. A.; Boyle, L. A.; Arumov, A.; Patil, S.; Edelweiss, M.; DeFusco, P. A.; Gorsky, M.; Lamparella, N. E.; Modi, S.; Sanford, R. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with implementation of point of care (POC) testing
    Meeting Abstract

    Symecko, H.; Mueller, R.; Spielman, K.; Batson, M.; Pundock, S.; Hamilton, J. G.; Robson, M. E.; Domchek, S. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC)
    Meeting Abstract

    Sherman, E. J.; Tsai, C. J.; Zhi, W. I.; Fetten, J. V.; Wu, V.; Ho, A. L.; Riaz, N.; Pfister, D. G.; Lee, N. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Effects of non-linear or linear aerobic training (AT) dosing regimens on impaired cardiovascular (CV) function in patients with operable breast cancer: A randomized controlled trial (RCT)
    Meeting Abstract

    Scott, J.; Thomas, S. M.; Herndon, J. E.; Peppercorn, J. M.; Douglas, P. S.; Khouri, M.; Dang, C. T.; Yu, A. F.; Catalina, D.; Ciolino, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results
    Meeting Abstract

    Rugo, H. S.; Borrego, M. R.; Chia, S. K. L.; Juric, D.; Turner, N. C.; Drullinsky, P.; Lerebours, F.; Bianchi, G. V.; Nienstedt, C. C.; Ridolfi, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC)
    Meeting Abstract

    Sammons, S.; Tan, T. J. Y.; Traina, T. A.; Kim, S. B.; Im, Y. H.; Bachelder, C.; Marcom, P. K.; Dent, R. A.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save